The evolving role of chemotherapy in prostate cancer.
作者信息
Saad Fred
机构信息
University of Montreal Hospital Center (CHUM) and Montreal Cancer Institute/CRCHUM, CHUM - Pavillon R 900, rue St-Denis, porte R10-464, Montréal, Québec H2X 0A9, Canada.
出版信息
Curr Opin Support Palliat Care. 2016 Sep;10(3):262-5. doi: 10.1097/SPC.0000000000000216.
PMID:27489183
Abstract
摘要
相似文献
1
The evolving role of chemotherapy in prostate cancer.化疗在前列腺癌中不断演变的作用。
Curr Opin Support Palliat Care. 2016 Sep;10(3):262-5. doi: 10.1097/SPC.0000000000000216.
2
Metastatic prostate cancer in 2015: The new and the old that is new again.2015年的转移性前列腺癌：新旧更替，旧貌换新颜。
Nat Rev Clin Oncol. 2016 Feb;13(2):73-4. doi: 10.1038/nrclinonc.2015.226. Epub 2015 Dec 31.
3
Re: Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.关于：醋酸阿比特龙在接受多西他赛化疗后的老年转移性去势抵抗性前列腺癌患者亚组（75岁及以上）中的疗效和安全性。
J Urol. 2015 Feb;193(2):541. doi: 10.1016/j.juro.2014.11.039. Epub 2014 Nov 15.
4
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?一刀切并不适用于所有情况：我们能否为无症状去势抵抗性前列腺癌患者选择最佳治疗顺序？
Eur Urol. 2014 Oct;66(4):653-4. doi: 10.1016/j.eururo.2014.03.024. Epub 2014 Mar 31.
5
The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.“人工”多西他赛领域：转移性去势抵抗性前列腺癌不断演变的治疗模式
Eur Urol. 2015 Jan;67(1):30-32. doi: 10.1016/j.eururo.2014.07.030. Epub 2014 Aug 6.
6
Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.去势抵抗性前列腺癌：2013年我们所处的位置以及泌尿外科医生应该了解的内容。
Eur Urol. 2013 Aug;64(2):260-5. doi: 10.1016/j.eururo.2013.05.021. Epub 2013 May 14.
7
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.细胞毒性化疗在转移性前列腺癌患者管理中的角色演变
Curr Treat Options Oncol. 2015 Feb;16(2):9. doi: 10.1007/s11864-014-0324-2.
8
Making progress on progression in metastatic prostate cancer.转移性前列腺癌进展方面取得进展。
J Clin Oncol. 2015 Apr 20;33(12):1322-4. doi: 10.1200/JCO.2014.59.4283. Epub 2015 Feb 9.
9
The timing of radium-223 therapy in castration-resistant prostate cancer.镭-223治疗去势抵抗性前列腺癌的时机
Clin Adv Hematol Oncol. 2015 Sep;13(9):570-2.
10
Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.回复：迈克尔·T·施韦泽、周先成、王浩等。既往阿比特龙治疗对多西他赛在转移性去势抵抗性前列腺癌男性患者中临床活性的影响。《欧洲泌尿外科杂志》2014年；66卷：646 - 52页。
Eur Urol. 2015 Jun;67(6):e113-e114. doi: 10.1016/j.eururo.2014.12.018. Epub 2014 Dec 17.
Zotero 插件